Erythropoietin Stimulating Agents (ESA)

November 27th, 2017 - Wyn Staheli, Director of Research
Categories:   Documentation Guidelines   Billing   Modifiers  

Coverage

ESA is typically covered for the following condition(s):

It could also be covered as preoperative treatment for patients undergoing a surgery (e.g., knee or hip replacement) when both the following are met:

  • patient is expected to lose more than 2 units of blood
  • patient has anemia and is not a good candidate for transfusions

Documentation

Before beginning ESA therapy, be sure to document (where applicable) any underlying causes of anemia which have been considered, and corrected where possible, such as:

  • Underlying infection or inflammatory process
  • Underlying hematological disease
  • Hemolysis
  • Vitamin deficiencies (e.g. folic acid or B12)
  • Blood loss
  • Aluminum intoxication

Comprehensive assessment which includes the following:

  • Hematocrit or hemoglobin
  • Serum iron
  • Transferrin saturation; or serum ferritin and /or documentation of iron stores in bone marrow
    Creatinine
  • Bone Marrow Biopsy (for myelodysplastic disease or where otherwise indicated)
  • Erythropoietin level (for myelodysplastic disease; AZT therapy, anemia of chronic disease)

Commonly Associated Modifiers: AYEA , EBECEDEEGSJAJB

Billing Note

Medicare will generally only covers ESRD-related drugs and biologicals when be billed by the renal dialysis facility. However, if an ESRD-related drug or biological was furnished to an ESRD beneficiary for reasons other than for the treatment of ESRD, it may be billed separately using modifier AY.

ESRD-related EPO is included in ESRD payment system and thus are not separately payable via Part B claims, however, there can be an exception for hospital billing when there is an emergency or unscheduled dialysis session.

Payer Guidelines

Be sure to verify coverage and review treatment policies with individual commercial payers or your Medicare Administrative Contractor (MAC) before beginning treatment. To review your MAC-specific carrier LCD, check the [Medicare Policies & Guidelines] portion shown below the code.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

COVID Vaccine Coding Changes as of November 1, 2023
October 26th, 2023 - Wyn Staheli
COVID vaccine changes due to the end of the PHE as of November 1, 2023 are addressed in this article.
Medicare Guidance Changes for E/M Services
October 11th, 2023 - Wyn Staheli
2023 brought quite a few changes to Evaluation and management (E/M) services. The significant revisions as noted in the CPT codebook were welcome changes to bring other E/M services more in line with the changes that took place with Office or Other Outpatient Services a few years ago. As part of CMS’ Medicare Learning Network, the “Evaluation and Management Services Guide” publication was finally updated as of August 2023 to include the changes that took place in 2023. If you take a look at the new publication (see references below),....
Can We Score Interpretation of an EKG Towards E/M Medical Decision Making?
October 10th, 2023 - Aimee Wilcox
When EKGs are performed in the facility setting or even in the physician's office, what are the requirements for reporting the service and who gets credit for scoring data points for Evaluation and Management (E/M) medical decision making (MDM)? Let's take a look at a few coding scenarios related to EKG services to get a better understanding of why this can be problematic.
Accurately Reporting Signs and Symptoms with ICD-10-CM Codes
October 5th, 2023 - Aimee Wilcox
Coders often find themselves unsure of when to report a sign or symptom code documented in the medical record. Some coders find their organization has an EHR that requires a working diagnosis, which is usually a sign or symptom, be entered to order a test or diagnostic study or image. Understanding the guidelines surrounding when signs and symptoms should be reported is the first step in correct coding so let's take a look at some scenarios.
The 2024 ICD-10-CM Updates Include New Codes for Reporting Metabolic Disorders and Insulin Resistance
September 19th, 2023 - Aimee Wilcox
Diabetes is a chronic disease that just seems to consistently be increasing instead of improving resulting in a constant endeavor by medical researchers to identify causal effects and possible treatments. One underlying or precipitating condition that scientists have identified as a precipitating factor in the development of diabetes is insulin resistance, which is a known metabolic disorder. As data becomes available through claims reporting, additional code options become possible with ICD-10-CM.
Documenting and Reporting Postoperative Visits
September 12th, 2023 - Aimee Wilcox
Sometimes we receive questions regarding documentation requirements for specific codes or coding requirements and we respond with information and resources to support our answers. The following question was recently submitted: Are providers required to report postoperative services on claims using 99024, especially if there is no payment for that service? What documentation is required if you are reporting an unrelated Evaluation and Management (E/M) service by the same physician during the postoperative period? 
Understanding Gastroesophageal Reflux Disease and ICD-10-CM Coding
August 22nd, 2023 - Aimee Wilcox
Gastroesophageal reflux disease or GERD for short, is a disease that impacts millions of Americans on a weekly basis. Symptoms are uncomfortable, as are some of the tests used to diagnose it, but understanding the disease, tests, and treatments helps us better understand how to code the disease using ICD-10-CM codes.



Home About Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2023 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association